Grail executives were upbeat on study results for the Galleri multi-cancer early detection test, while ASCO said more ...
Grail's multi-cancer blood test can find cancer — but there's still one big problem with how it works.
Despite a disappointing trial result, there's still a case for buying the stock, with a near-term catalyst on the horizon.
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a broad strategic collaboration with AstraZeneca ...
Top 10 Stock Picks and GRAIL, Inc. (NASDAQ:GRAL) ranks 8th on this list. The interest of Jeff Bezos in GRAIL, Inc. (NASDAQ:GRAL) can be understood in context of the history of Bezos as a backer of ...
The company recently reported better-than-expected results, and investors are hoping for more positive news at the end of the month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results